When it comes to covid-19 vaccines, poor countries in Africa have been stuck at the back of the queue. However, the continent’s long wait for another immunological miracle appears to be drawing to a close. Later this year, the world’s first malaria vaccine is scheduled for a roll-out. Although the current version leaves much to be desired—it requires four doses, is hard to manufacture at scale and reduces severe infections by a mere 30%—better alternatives may be on the way. A jab developed by scientists at Oxford has shown 77% effectiveness. If clinical trials go well, they aim to apply for pre-qualification from the World Health Organisation in September. Production at a rate of up to 200m doses per year could follow swiftly.
https://www.geneconvenevi.org/wp-content/uploads/2020/04/The-Economist-2.png300300David Obrochta/wp-content/uploads/2019/10/GC-color-logo-for-header-3277-x-827-1030x260.pngDavid Obrochta2022-03-19 06:25:312022-03-20 06:31:54Squashing malaria could save as many lives as covid-19 has taken